BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24366361)

  • 21. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
    Iacobucci I; Lonetti A; Messa F; Cilloni D; Arruga F; Ottaviani E; Paolini S; Papayannidis C; Piccaluga PP; Giannoulia P; Soverini S; Amabile M; Poerio A; Saglio G; Pane F; Berton G; Baruzzi A; Vitale A; Chiaretti S; Perini G; Foà R; Baccarani M; Martinelli G
    Blood; 2008 Nov; 112(9):3847-55. PubMed ID: 18650450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
    Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of childhood ALL using
    Hovorkova L; Zaliova M; Venn NC; Bleckmann K; Trkova M; Potuckova E; Vaskova M; Linhartova J; Machova Polakova K; Fronkova E; Muskovic W; Giles JE; Shaw PJ; Cario G; Sutton R; Stary J; Trka J; Zuna J
    Blood; 2017 May; 129(20):2771-2781. PubMed ID: 28331056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
    Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
    Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IKZF1 (IKAROS) deletions in B-ALL and its clinical correlation: A prospective study from a tertiary care centre in Northern India.
    Gupta SK; Bakhshi S; Kumar L; Seth R; Kumar R
    Leuk Res; 2016 Feb; 41():7-11. PubMed ID: 26704074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Piccaluga PP; Paolini S; Martinelli G
    Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
    Li H; Zhang W; Kuang P; Ye Y; Yang J; Dai Y; Lu X; Zheng Y; Liu T
    Leuk Lymphoma; 2018 Aug; 59(8):1890-1898. PubMed ID: 29214878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XY; Han W; Zhang XH; Wang Y; Zhang YY; Qin YZ; Liu YR; Huang XJ
    J Hematol Oncol; 2012 Jun; 5():29. PubMed ID: 22682059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study.
    Yeoh AEJ; Lu Y; Chin WHN; Chiew EKH; Lim EH; Li Z; Kham SKY; Chan YH; Abdullah WA; Lin HP; Chan LL; Lam JCM; Tan PL; Quah TC; Tan AM; Ariffin H
    J Clin Oncol; 2018 Sep; 36(26):2726-2735. PubMed ID: 30044693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
    Branford S; Yeung DT; Parker WT; Roberts ND; Purins L; Braley JA; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Donaldson Z; Leong M; Fletcher L; Seymour JF; Grigg AP; Ross DM; Hughes TP
    Blood; 2014 Jul; 124(4):511-8. PubMed ID: 24859364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Significance of IKZF1 gene copy number abnormalities in BCR/ABL-negative B-lineage acute lymphoblastic leukemia in children].
    Zou Y; Liu XM; Zhang L; Chen YM; Guo Y; Chen XJ; Yang WY; Wang SC; Ruan M; Liu TF; Zhang JY; Liu F; Qi BQ; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Nov; 17(11):1154-9. PubMed ID: 26575870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Stock W
    Leuk Lymphoma; 2010 Feb; 51(2):188-98. PubMed ID: 20001232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.
    Churchman ML; Low J; Qu C; Paietta EM; Kasper LH; Chang Y; Payne-Turner D; Althoff MJ; Song G; Chen SC; Ma J; Rusch M; McGoldrick D; Edmonson M; Gupta P; Wang YD; Caufield W; Freeman B; Li L; Panetta JC; Baker S; Yang YL; Roberts KG; McCastlain K; Iacobucci I; Peters JL; Centonze VE; Notta F; Dobson SM; Zandi S; Dick JE; Janke L; Peng J; Kodali K; Pagala V; Min J; Mayasundari A; Williams RT; Willman CL; Rowe J; Luger S; Dickins RA; Guy RK; Chen T; Mullighan CG
    Cancer Cell; 2015 Sep; 28(3):343-56. PubMed ID: 26321221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
    Tachibana T; Najima Y; Akahoshi Y; Hirabayashi S; Harada K; Doki N; Uchida N; Fukuda T; Sawa M; Ogata M; Takada S; Tanaka M; Matsuhashi Y; Tanaka J; Onizuka M; Ichinohe T; Atsuta Y; Kako S;
    Ann Hematol; 2020 Oct; 99(10):2393-2404. PubMed ID: 32803312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia.
    Mangum DS; Meyer JA; Mason CC; Shams S; Maese LD; Gardiner JD; Downie JM; Pei D; Cheng C; Gleason A; Luo M; Pui CH; Aplenc R; Hunger SP; Loh M; Greaves M; Trede N; Raetz E; Frazer JK; Mullighan CG; Engel ME; Miles RR; Rabin KR; Schiffman JD
    JAMA Oncol; 2021 Oct; 7(10):1521-1528. PubMed ID: 34410295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia".
    Palmi C; Lana T; Silvestri D; Savino A; Kronnie GT; Conter V; Basso G; Biondi A; Valsecchi MG; Cazzaniga G
    Haematologica; 2013 Dec; 98(12):e164-5. PubMed ID: 24323991
    [No Abstract]   [Full Text] [Related]  

  • 40. Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.
    Huang Z; Jia Y; Ruan G; Zuo Y; Wu J; Lu A; Xue Y; Cheng Y; Zhang L
    Pediatr Hematol Oncol; 2022 Apr; 39(3):243-253. PubMed ID: 34582325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.